<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00747487</url>
  </required_header>
  <id_info>
    <org_study_id>SNT-II-003</org_study_id>
    <nct_id>NCT00747487</nct_id>
  </id_info>
  <brief_title>Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy</brief_title>
  <acronym>RHODOS</acronym>
  <official_title>A Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Patients With Leber's Hereditary Optic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santhera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santhera Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is meant to assess the effectiveness of idebenone on visual function measures in
      patients with Leber's Hereditary Optic Neuropathy over a 6 months period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study involves 6 clinic visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best recovery of logMAR visual acuity between baseline and Week 24 in either right or left eye</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the patient's best logMAR visual acuity between baseline and week 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in scotoma area in both eyes</measure>
    <time_frame>Day -1, Week 4, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in optic nerve fibre layer thickness in both eyes</measure>
    <time_frame>Day -1, Week 4, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colour contrast sensitivity in both eyes (in a subset of patients)</measure>
    <time_frame>Day -1, Week 4, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>logMAR visual acuity as a continuous variable in both eyes</measure>
    <time_frame>Screening, Day -1, Week 4, Week 12, Week 24, Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change</measure>
    <time_frame>Week 4, Week 12 and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health-Related Quality of Life (HRQOL)</measure>
    <time_frame>Day -1, Week 4, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-reported general energy levels</measure>
    <time_frame>Day -1, Week 4, Week 12, Week 24, Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in which visual acuity in the initially least affected eye does not deteriorate to 1.0 log MAR or more ( in LHON patients with eye still less affected than 0.5 logMAR at trial entry)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of idebenone matched to measures of efficacy and safety</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Best visual acuity at Week 24 (best eye at Week 24) compared to best visual acuity at Baseline (best eye at Baseline)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Count of eyes/ patients for which the visual acuity improves between baseline and week 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Leber's Hereditary Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idebenone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idebenone</intervention_name>
    <description>Idebenone 900 mg/day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; or = 14 years and &lt; 65 years

          -  Impaired visual acuity in at least one eye due to LHON

          -  Onset of visual loss due to LHON lies five years or less prior to Baseline

          -  Confirmation of either G11778A, T14484C or G3460A LHON mtDNA mutations at &gt;60% in
             blood

          -  No explanation for the visual failure besides LHON

          -  Body weight ≥ 45 kg

          -  Negative urine pregnancy test at Screening and at Baseline (women of childbearing
             potential).

        Exclusion Criteria:

          -  Treatment with Coenzyme Q10 or idebenone within 1 month prior to Baseline

          -  Pregnancy and/or breast-feeding

          -  Weekly alcohol intake 35 units (men) or 24 units (women)

          -  Current drug abuse

          -  Clinically significant abnormalities of clinical haematology or biochemistry
             including, but not limited to, elevations greater than 2 times the upper limit of
             normal of AST, ALT or creatinine

          -  Participation in another clinical trial of any investigational drug within 3 months
             prior to Baseline

          -  Other factor that, in the investigator's opinion, excludes the patient from entering
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Patrick F Chinnery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Facility, 4th Floor Leazes Wing, Royal Victoria Infirmary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof Thomas Klopstock, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Universität München - Grosshadern, Neurologische Klinik und Poliklinik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unité de recherche clinique Ophtalmologie- Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München - Grosshadern, Neurologische Klinik und Poliklinik</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Facility, 4th Floor Leazes Wing, Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.santhera.com/index.php?mid=101&amp;vid=&amp;lang=en</url>
    <description>Website for LHON patients in Canada</description>
  </link>
  <link>
    <url>http://lhon.ncl.ac.uk/</url>
    <description>Website for LHON patients in the U.K.</description>
  </link>
  <results_reference>
    <citation>Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M, Atawan A, Chattopadhyay S, Schubert M, Garip A, Kernt M, Petraki D, Rummey C, Leinonen M, Metz G, Griffiths PG, Meier T, Chinnery PF. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain. 2011 Sep;134(Pt 9):2677-86. doi: 10.1093/brain/awr170. Epub 2011 Jul 25.</citation>
    <PMID>21788663</PMID>
  </results_reference>
  <results_reference>
    <citation>Rudolph G, Dimitriadis K, Büchner B, Heck S, Al-Tamami J, Seidensticker F, Rummey C, Leinonen M, Meier T, Klopstock T. Effects of idebenone on color vision in patients with leber hereditary optic neuropathy. J Neuroophthalmol. 2013 Mar;33(1):30-6. doi: 10.1097/WNO.0b013e318272c643.</citation>
    <PMID>23263355</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2008</study_first_submitted>
  <study_first_submitted_qc>September 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2008</study_first_posted>
  <last_update_submitted>May 24, 2013</last_update_submitted>
  <last_update_submitted_qc>May 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leber</keyword>
  <keyword>LHON</keyword>
  <keyword>Leber's Hereditary Optic Neuropathy</keyword>
  <keyword>Idebenone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Atrophy, Hereditary, Leber</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idebenone</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

